American Association for Cancer Research
23266066cir150046-sup-145284_2_supp_3014763_nps5dw.docx (126.04 kB)

Supplementary Methods from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma

Download (126.04 kB)
journal contribution
posted on 2023-04-03, 23:03 authored by Sarah Derks, Katie S. Nason, Xiaoyun Liao, Matthew D. Stachler, Kevin X. Liu, Jie Bin Liu, Ewa Sicinska, Michael S. Goldberg, Gordon J. Freeman, Scott J. Rodig, Jon M. Davison, Adam J. Bass

Supplementary Methods



Esophageal adenocarcinoma is an increasingly common disease with a dismal 5-year survival rate of 10% to 15%. In the first systematic evaluation of the PD-1 pathway in esophageal adenocarcinoma, we identify expression of PD-L2 in cancer cells in 51.7% of esophageal adenocarcinomas. Epithelial PD-L1 was expressed on only 2% of cases, although PD-L1+ immune cells were observed in 18% of esophageal adenocarcinomas. We also evaluated expression in the precursor lesion of esophageal adenocarcinoma, Barrett's esophagus, which emerges following gastric reflux–induced esophageal inflammation, and found PD-L2 expression in Barrett's esophagus but not in non–Barrett's esophagus esophagitis. Because the progression from squamous esophagitis to Barrett's esophagus is accompanied by a transition from a TH1 to TH2 immune response, we hypothesized that the TH2 cytokines IL4/IL13 could contribute to PD-L2 induction. We confirmed that these cytokines can augment PD-L2 expression in esophageal adenocarcinoma cell lines. These results suggest that the inflammatory environment in Barrett's esophagus and esophageal adenocarcinoma may contribute to the expression of PD-L2. Furthermore, the potential for PD-1 receptor blockade to be effective in esophageal adenocarcinomas with epithelial PD-L2 or immune cell PD-L1 expression should be evaluated in clinical trials. Cancer Immunol Res; 3(10); 1123–9. ©2015 AACR.

Usage metrics

    Cancer Immunology Research



    Ref. manager